基本信息
views: 30
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Diabetes and hypertension are major causes of end-stage kidney disease. A/Prof Tesch’s research focuses on identifying the underlying mechanisms of inflammation and fibrosis that are involved in kidney and heart injury in patients with diabetes and hypertension. In particular, his work focuses on the role of macrophages, tubular cells, fibroblasts and cell signalling pathways in progressive tissue injury. His studies utilize a variety of experimental techniques to examine the molecular mechanisms of disease, including conditional gene deletion, pharmacological blockade of receptors or intracellular signalling kinases, combination therapies, and cell culture studies. He is also engaged in a collaboration to develop novel drug delivery systems to target specific cell types. His previous work has led to clinical trials using an inhibitor of either a chemokine receptor (CCR2) or a specific kinase (ASK1) to treat diabetic kidney disease. This has been achieved through collaborations with local and overseas researchers, and with a number of commercial companies.
Research Interests
Papers共 195 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical science (London, England : 1979)no. 5 (2024): 309-326
Fan Yang,Elyce Ozols, Y. Frank,Khai Gene Leong,Greg H. Tesch,Jiang Xiao-yun, David J. Nikolic‐Paterson
Frontiers in Physiology (2023)
Integrative Medicine in Nephrology and Andrologyno. 2 (2023)
The American Journal of Pathologyno. 3 (2022): 441-453
The American Journal of Pathologyno. 3 (2022): 441-453
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn